Pharmaceutical clinical trials have a dropout problem. Roughly 30% of participants leave before a trial ends, according to data from the Tufts Center for the Study of Drug Development. That attrition costs sponsors an estimated $19,533 per patient in recruitment replacement costs alone, and it delays timelines that are already painfully long. The average drug takes 10-15 years to go from lab to pharmacy shelf.
One contributor to dropout is simple inconvenience. Participants are asked to travel to clinical sites for vital sign measurements that take five minutes but consume half a day. Blood pressure, heart rate, respiratory rate, oxygen saturation — these readings require showing up, sitting in a waiting room, getting measured, and going home. For a trial that runs 12-18 months with biweekly visits, the burden adds up fast.
Camera-based vital sign monitoring through rPPG is starting to change this equation. The idea is straightforward: instead of requiring patients to visit a site for routine vital sign collection, let them do a 30-second video scan on their smartphone from home.
"Decentralized clinical trial designs that incorporate remote monitoring technologies can reduce participant burden by up to 70% while maintaining data integrity comparable to site-based collection." — Li et al., JAMA Network Open (2024)
Why drug trials are moving away from site-only data collection
The FDA published final guidance in September 2024 specifically addressing decentralized clinical trials (DCTs). The document, titled "Conducting Clinical Trials With Decentralized Elements," lays out a regulatory framework for moving trial activities — including vital sign monitoring — outside traditional clinical sites.
This wasn't a sudden shift. The COVID-19 pandemic forced sponsors to adopt remote monitoring when site visits became impossible, and the data showed that it worked. Between 2020 and 2023, the number of trials incorporating at least one decentralized element grew from roughly 7% to over 25%, according to a 2024 analysis published in the Journal of Medical Internet Research (JMIR) by Inan et al.
The reasons go beyond pandemic adaptation:
- Trial participant demographics skew heavily toward people who live near academic medical centers. Decentralized designs open enrollment to rural and underserved populations who would otherwise never participate.
- Continuous or frequent remote monitoring can capture vital sign data between scheduled visits, catching adverse events that would be missed with periodic site measurements.
- Younger participants in particular expect digital-first experiences. A 2023 survey by the Clinical Trials Transformation Initiative found that 68% of respondents aged 18-45 preferred trials with remote participation options.
How rPPG fits into clinical trial protocols
Camera-based vital sign monitoring using rPPG extracts physiological signals from facial video. When light hits the skin, some of it penetrates the tissue and interacts with blood flowing through capillaries. Each heartbeat causes a tiny change in blood volume that alters how light is absorbed and reflected. These changes are invisible to the human eye but detectable by a camera sensor.
From that video signal, algorithms can derive heart rate, heart rate variability, respiratory rate, and blood oxygen saturation. Blood pressure estimation from facial video is also an active research area, with groups at institutions including the University of Toronto and TU Eindhoven publishing results that show correlation with cuff-based measurements, though with wider error margins.
In a trial context, the workflow looks like this: a participant opens an app on their phone, holds it at face level for 30 seconds, and the app captures a video scan. The rPPG algorithms process the video locally or in the cloud, extract vital signs, and submit them directly to the trial's electronic data capture (EDC) system. No additional hardware. No site visit.
| Data collection method | Site visit required | Measurement time | Equipment cost per patient | Data frequency | Patient burden |
|---|---|---|---|---|---|
| Traditional site monitoring | Yes | 15-30 min (plus travel) | $200-500 (amortized) | Biweekly to monthly | High |
| Wearable biosensor patch | No | Continuous | $150-400 per device | Continuous | Moderate (adhesion, charging) |
| Connected cuff/oximeter | No | 2-5 min per reading | $80-250 per device | Daily (manual) | Moderate (device management) |
| Smartphone rPPG | No | 30-60 seconds | $0 (uses existing phone) | Daily or more | Low |
| Clinic-grade telemetry | Yes (or home setup) | Continuous | $1,000-5,000 | Continuous | High (setup complexity) |
Sources: Tufts CSDD cost data (2023), FDA DCT guidance (2024), industry sponsor estimates.
The cost advantage of smartphone-based rPPG is hard to ignore. Wearable patches and connected devices require manufacturing, shipping, tech support, and returns logistics. Smartphones are already in participants' pockets.
Real regulatory movement: the Mindset Medical 510(k)
In November 2024, the FDA cleared Mindset Medical's IVC App through the 510(k) pathway — a camera-based application that uses rPPG to estimate pulse rate from real-time video captured on a computer, laptop, or mobile device. The clearance letter (K241633) specifically describes the use of "Remote Photoplethysmography (rPPG) technique" for "detecting volumetric changes in blood in peripheral circulation."
This clearance matters for clinical trials because it establishes a regulatory precedent. Sponsors can now point to an FDA-reviewed rPPG device when discussing camera-based vital sign collection with regulatory agencies during pre-IND or protocol review meetings. It doesn't mean every rPPG implementation is cleared — but it means the technology class has passed the FDA's threshold for safety and effectiveness in at least one configuration.
What the validation data shows
Several groups have published clinical validation studies relevant to trial use:
Verkruysse, Svaasand, and Nelson (2008) at UC Irvine first demonstrated that ambient-light facial video contained physiological information. Their work opened the field, though the accuracy was limited by the technology available at the time.
Wong et al. (2022) presented the VITALS platform at the IEEE/ACM Conference on Connected Health, demonstrating a camera-based system for multi-vital-sign capture that could integrate with clinical monitoring workflows. Their data showed heart rate agreement within ±3 BPM in controlled settings.
A medRxiv preprint by the WellFie study team (2023) evaluated smartphone-based rPPG vital sign accuracy in a hospital setting, comparing readings against approved reference monitors. The study found acceptable agreement for heart rate and respiratory rate, with blood pressure showing wider variance.
Di Lernia et al. (2024) published in Behavior Research Methods on rPPG performance "in the wild" — measuring heart rate from online webcam feeds under uncontrolled conditions. Their results demonstrated that modern algorithms maintain reasonable accuracy even outside laboratory environments, which is directly relevant to at-home trial participation.
A comprehensive review by Pirzada et al. (2024) in IEEE Sensors Journal cataloged the state of rPPG for heart rate and blood oxygenation measurement, noting that deep learning approaches have substantially closed the accuracy gap with contact-based sensors.
Where the gaps remain
The technology isn't ready to replace site-based monitoring for everything. Accuracy varies with lighting conditions, skin tone, motion artifacts, and camera quality — variables that are controlled in a clinic but wildly inconsistent in someone's living room.
Blood pressure estimation from facial video remains the biggest open question. While several research groups have demonstrated correlation, the error margins are still too wide for most cardiovascular trial endpoints. Heart rate and respiratory rate are closer to clinical utility; SpO2 is somewhere in between.
There's also the question of data standardization. When 500 trial participants are sending video scans from 200 different phone models under varying lighting conditions, ensuring comparable data quality is a non-trivial engineering challenge. The FDA's DCT guidance acknowledges this, noting that sponsors need robust data quality monitoring plans for remote collection technologies.
Ba et al. (2023) raised equity concerns that matter directly for trials: melanin content affects rPPG signal quality, and if diverse populations are underrepresented in algorithm training data, the technology could introduce measurement bias into trial results — exactly the opposite of what decentralized designs are supposed to achieve.
What this means for the next five years
The pharmaceutical industry spends roughly $50 billion annually on clinical trials globally, according to McKinsey estimates. Even modest improvements in retention rates and data collection efficiency represent billions in savings. That economic pressure is why nearly every major CRO and top-20 pharma company has at least one active initiative around remote digital vital sign monitoring.
Camera-based rPPG is one piece of a broader shift toward passive, low-burden data collection. The smartphone is becoming the clinical instrument — not because phone cameras are better than medical devices, but because a measurement that actually gets taken beats a precise measurement that doesn't.
Circadify has developed camera-based vital sign monitoring technology and is working with sponsors and CROs to integrate it into decentralized and hybrid trial protocols. The technology captures heart rate, respiratory rate, HRV, and SpO2 from a standard smartphone camera, with data flowing directly into clinical trial management systems.
The regulatory path is clearing. The validation data is accumulating. And the economic incentive is enormous. Camera-based vital signs won't replace the clinical site — but they're going to make the clinical site optional for a lot of routine measurements.
Frequently asked questions
Can camera-based vital signs be used in FDA-regulated clinical trials?
Yes. The FDA's September 2024 guidance on decentralized clinical trials supports remote digital health technologies for data collection. Camera-based rPPG systems that have received 510(k) clearance, such as Mindset Medical's IVC App cleared in November 2024, can be used for specific vital sign measurements in trial protocols.
What vital signs can rPPG measure during a clinical trial?
Current rPPG technology can measure heart rate, heart rate variability, respiratory rate, and blood oxygen saturation from a standard smartphone or webcam video. Blood pressure estimation is an active area of research with several groups publishing results, though accuracy varies by method.
How does contactless monitoring improve patient retention in trials?
Patients in decentralized trials using remote monitoring tools report higher satisfaction and lower dropout rates because they spend less time traveling to clinical sites. Decentralized trial designs have been shown to reduce participant burden significantly compared to traditional site-based protocols.
Is rPPG accurate enough for clinical-grade data collection?
Published validation studies show rPPG heart rate measurement within ±2-5 BPM of reference devices in controlled conditions. Accuracy depends on lighting, motion, and camera quality. Clinical trials typically use rPPG for screening and trending rather than replacing gold-standard monitoring equipment.
Related Articles
- What is rPPG Technology? — The complete overview of remote photoplethysmography and the vital signs it can measure.
- Remote Patient Monitoring Reduces Readmissions — How remote monitoring improves outcomes outside the clinical trial context.
- Privacy and Data Security in Camera-Based Health Monitoring — Security considerations that apply directly to handling trial participant video data.